Celator Pharmaceuticals, Inc. Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Hematology Annual Meeting
12/7/2010 10:00:14 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 (Cytarabine:Daunorubicin) Liposome Injection. Data were presented from the podium at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. The results were based on 12 months of follow-up in a randomized, Phase 2 trial that compared CPX-351 to conventional cytarabine and daunorubicin (the “7+3” regimen), the current standard of care (ASH Abstract #655).